J. Robert Coleman

Codagenix scores again: $3M to hunt down deadly RSV

By GREGORY ZELLER // A fresh $3 million in public and private investments has set Codagenix Inc. on the trail of another nefarious disease. Already developing vaccines for Zika virus, the mutating menace Influenza A and a host of other viral villains, Codagenix will now focus its vaccine-creation might on Respiratory Syncytial Virus through a $1.5 million Phase II Small Business Innovation Research grant from the National Institutes of Health and another $1.5 million in…


Codagenix: Flu can mutate, but it can’t hide

By GREGORY ZELLER // In a potentially huge breakthrough in the struggle against seasonal influenza mutations, Codagenix Inc. is preparing to release data demonstrating “multi-season efficacy” for its frontline flu vaccine – meaning the vaccine could prevent flu-related sicknesses even after the virus mutates. According to the Farmingdale-based clinical-stage startup, in multiple studies involving pigs and ferrets, CodaVax-H1N1 – Codagenx’s live-attenuated Influenza A vaccine – induced “a robust immune response to multiple seasonal strains of…


Codagenix, SUNY RF ink exclusive licensing deal

A year of big steps has led to one giant leap for Codagenix. Stony Brook University, through the Research Foundation for the State University of New York, has entered into an exclusive licensing agreement with the Farmingdale-based biotech to commercialize a platform technology aiming to create a “pipeline of live attenuated vaccines” against viral infections attacking humans and other animals. The exclusive licensing agreement, announced Wednesday, involves technology developed in the laboratory of Eckard Wimmer,…


Codagenix commences Zika vaccine testing

By GREGORY ZELLER // Farmingdale biotech Codagenix Inc. has commenced the first tests of its potential Zika virus vaccines in a living host. In a noteworthy display of speed sure to impress the medical community and potential investors alike, the 2012 startup began in vivo testing of its live-attenuated Zika virus vaccine candidates earlier this month – just 27 days after it plugged Zika into its proprietary, synthetic biology-based vaccine-design platform. The safety and efficacy study…


Some pig: USDA, Codagenix target swine flu

By GREGORY ZELLER // With Zika virus, Foot and Mouth Disease and other global threats already in its crosshairs, Farmingdale biotech Codagenix Inc. is challenging another high-profile opponent: swine flu. A Phase I Small Business Innovation Research grant from the U.S. Department of Agriculture will fund research and development of an influenza vaccine for swine using Codagenix’s proprietary software platform, which “re-codes” viruses to create and test potential vaccines. Research and development under the $99,710…


Move complete, Codagenix takes aim at Zika

By GREGORY ZELLER // Be afraid, Zika virus. With 1,500 square feet of new wet-lab space and buckets of confidence, the big thinkers at Codagenix are targeting your chemical code – with a candidate vaccine likely ready for animal testing inside of six weeks. So says J. Robert Coleman, the Farmingdale State College biology professor who cofounded the 2012 startup with Stony Brook University assistant research professor Steffen Mueller. Zika is a flavivirus – a…


Codagenix preps for fight against Zika virus

By GREGORY ZELLER // A Stony Brook startup that digitally recreates viruses in order to reprogram their genomes is preparing to take on the Zika virus, which World Health Organization officials said Thursday is “spreading explosively” through the Americas. Codagenix, a 2012 startup cofounded by Farmingdale State College biology professor J. Robert Coleman and former Stony Brook University assistant research professor Steffen Mueller, is keeping a close eye on the migration of the virus, which…


Codagenix making all the right moves

By GREGOERY ZELLER // A seven-figure Regional Economic Development Council award is set to push an innovative influenza vaccine toward human trials. Codagenix, a 2012 startup cofounded by Farmingdale State College biology professor J. Robert Coleman and former Stony Brook University assistant research professor Steffen Mueller, received $2.25 million through the 2015 REDC awards, which were announced in December. All told, 121 Long Island projects collected $98.3 million through the fifth-annual REDC process, many focused…